AbbVie jumps into $405M CF deal with Galapagos

AbbVie ($ABBV) is on a roll. One day after the U.S.-based drugmaker announced an $840 million deal with Ablynx to develop a new anti-inflammatory drug, AbbVie said it has inked a $405 million deal with Belgium's Galapagos to target genetic mutations in patients with cystic fibrosis. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.